ENTA
Enanta Pharmaceuticals Inc
NASDAQ · Biotechnology
$13.51
+0.54 (+4.16%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 88.85M | 97.45M | 82.68M | 75.01M | 89.50M |
| Net Income | -111,375,994 | -109,946,687 | -22,888,047 | -19,564,680 | -21,049,434 |
| EPS | — | — | — | — | — |
| Profit Margin | -125.4% | -119.1% | -27.7% | -26.1% | -23.5% |
| Rev Growth | -8.8% | -8.8% | -7.4% | -3.9% | +22.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 134.99M | 134.99M | 84.29M | 78.78M | 74.71M |
| Total Equity | 61.03M | 61.03M | 230.34M | 195.69M | 201.77M |
| D/E Ratio | 2.21 | 2.21 | 0.37 | 0.40 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -109,843,816 | -114,458,292 | -23,098,769 | -21,379,947 | -25,062,209 |
| Free Cash Flow | — | — | -13,628,189 | -13,998,479 | -22,107,180 |